×

CellRapeutics™ CD19+ B Cells from Type 1 Diabetes Donor (XS-0426-XU9)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

These high-purity CD19+ B cells are harvested from T1D patients exhibiting autoimmune destruction of pancreatic beta cells. This product is a vital resource for deciphering the early stages of insulitis, specifically the B cell's role as a potent antigen-presenting cell that facilitates the activation of autoreactive T-lymphocytes against islet antigens.

Specific Inquiry

  • Size:
  Add to Cart

Donor Information

  • Product Name
  • CellRapeutics™ CD19+ B Cells from Type 1 Diabetes Donor
  • Cat. No.
  • XS-0426-XU9
  • Donor Age
  • Pediatric, Young Adult
  • Donor Health
  • Diagnosed with Type 1 Diabetes Mellitus (T1DM). Donors exhibit clear autoimmune destruction profiles of pancreatic beta cells, often with detectable islet cell autoantibodies.
  • Ethnicity
  • Diverse backgrounds available, predominantly Caucasian.
  • Anticoagulant
  • Acid Citrate Dextrose, optimized for precise pH buffering to protect sensitive autoimmune B-cell subsets from metabolic acidosis and preserve antigen-presenting functionality.
  • Additional Donor Information
  • Each lot features CD19+ B cells from donors with Type 1 Diabetes. Information includes age of onset, C-peptide levels, and presence of islet-specific autoantibodies, essential for researching B-cell roles in autoimmune pancreatic beta-cell destruction.
  • Clinical Profile
  • Age of onset, presence of islet autoantibodies, daily insulin requirement, and frequency of ketoacidosis episodes.

Additional Information

  • Medication History
  • Available upon request. Primarily documents insulin replacement therapy regimens and any history of participation in clinical trials involving immunomodulatory agents to preserve beta-cell function.
  • Formulation
  • Cryopreserved in specialized freezing medium
  • Cell Purity
  • >90%
  • Cell Viability
  • >90%
  • Mycoplasma Testing
  • Negative
  • Sterility Testing
  • Negative
  • Genetic Stability Testing
  • The donor cells maintain their native genetic profile, exhibiting no karyotypic abnormalities or chromosomal instabilities typically associated with prolonged ex vivo expansion.
  • Application
  • Drug Discovery, Immuno-oncology Research
  • Research Use Only
  • RUO
  • Quality Control
  • Each product batch undergoes rigorous testing for purity, viability, and microbial contamination.
  • Storage
  • Upon arrival, immediately transfer the vial to the liquid nitrogen.
  • Shiping
  • Dry Ice
  • Handling Notes
  • Upon thawing, it is recommended to rapidly thaw the cells in a 37°C water bath, followed by the slow addition of pre-warmed culture medium to minimize osmotic shock.
  • Warnings
  • Treat as potentially biohazardous human-derived material and handle strictly under BSL-2 guidelines using appropriate personal protective equipment.
  • Size
  • 1E7 cells/vial, 2.5E7 cells/vial
  • Keywords
  • CellRapeutics™ CD19+ B Cells from Type 1 Diabetes Donor, CD19+ B Cells, Type 1 Diabetes

Case Studies

Customer Reviews and Q&As

There are currently no customer reviews or questions for CellRapeutics™ CD19+ B Cells from Type 1 Diabetes Donor (XS-0426-XU9). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

Key Updates
Newsletter. (Creative Biolabs Authorized) NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution. (Creative Biolabs Authorized) NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
Novel Solution. (Creative Biolabs Authorized) NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
New Technology. (Creative Biolabs Authorized) NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.